TSE:4151Pharmaceuticals
Kyowa Kirin (TSE:4151) Regains Rocatinlimab Control Is Its R&D Strategy Entering a New Phase?
On January 30, 2026, Amgen announced a termination agreement with Kyowa Kirin that will end their 2021 license and collaboration for eczema drug rocatinlimab, returning development and commercialization control to Kyowa Kirin once regulatory approvals to terminate take effect.
This move means Kyowa Kirin alone will decide whether and how to advance rocatinlimab, including planned regulatory submissions, after Amgen exited over portfolio and dosing concerns.
We’ll now examine how Kyowa Kirin...